Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I

  • Merz L
  • Zimmermann S
  • Peters S
  • et al.
7Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

? AlphaMed Press 2016.Background. Although the prevalence of non-AIDS-defining cancers (non-ADCs) among people living with HIV is rising, we observed HIV testing rates below 5% at our oncology center, againsta regional HIV prevalence of 0.2%-0.4%. We performed the Investigating Barriers in HIV-Testing Oncology Patients (IBITOP) study among oncology physicians and patients. Methods. Between July 1 and October 31, 2013, patients of unknown HIV status newly diagnosed with solid-organ non-ADCs referred to Lausanne University Hospital Oncology Service, Switzerland, were offered free HIV testing as part of their oncology work-up. The primary endpoints were (a) physician willingness to offer and patient acceptance of HIV testing and (b) physicians? reasons for not offering testing. Results. Of 239 patients of unknown HIV status with a new non-ADC diagnosis, 43 (18%) were offered HIV testing, of whom 4 declined (acceptance rate: 39 of 43; 91%). Except for 21 patients tested prior to oncology consultation, 175 patients (of 239; 73%) were not offered testing. Testing rate declined among patientswhowere >70 years old (12% versus 30%; p5 .04); no non-European patients were tested. Physicians gave reasons for not testing in 16% of cases, the main reason being patient follow-up elsewhere (10 patients; 5.7%). HIV testing during the IBITOP study increased the HIV testing rate to 18%. Conclusion. Although the IBITOP study increased HIV testing rates, most patients were not tested. Testing was low or nonexistent among individuals at risk of late HIV presentation (older patients and migrants). Barriers to testing appear to be physician-led, because patient acceptance of testing offered was very high (91%). In November 2013, the Swiss HIV testing recommendations were updated to propose testing in cancer patients. Phase II of the IBITOPstudy is examining the effect of these recommendations on HIV testing rates and focusing on physician-led testing barriers.

Cite

CITATION STYLE

APA

Merz, L., Zimmermann, S., Peters, S., Cavassini, M., & Darling, K. E. A. (2016). Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I. The Oncologist, 21(10), 1176–1182. https://doi.org/10.1634/theoncologist.2016-0107

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free